Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) released its earnings results on Tuesday. The biopharmaceutical company reported ($0.10) EPS for the quarter, meeting the consensus estimate of ($0.10), Bloomberg Earnings reports. Vanda Pharmaceuticals had a negative net margin of 6.54% and a negative return on equity of 7.85%. The firm had revenue of $41.30 million for the quarter, compared to analyst estimates of $43.90 million. During the same period last year, the firm earned ($0.01) EPS. The business’s quarterly revenue was up 7.3% compared to the same quarter last year.

Vanda Pharmaceuticals (NASDAQ VNDA) opened at $14.95 on Wednesday. Vanda Pharmaceuticals has a 1 year low of $12.70 and a 1 year high of $18.99.

ILLEGAL ACTIVITY NOTICE: This piece of content was originally posted by The Cerbat Gem and is the property of of The Cerbat Gem. If you are accessing this piece of content on another domain, it was illegally copied and republished in violation of US and international trademark and copyright legislation. The correct version of this piece of content can be read at https://www.thecerbatgem.com/2017/11/07/vanda-pharmaceuticals-inc-vnda-posts-quarterly-earnings-results-beats-expectations-by-0-12-eps.html.

Several equities analysts have commented on the stock. Zacks Investment Research raised shares of Vanda Pharmaceuticals from a “sell” rating to a “strong-buy” rating and set a $18.00 target price on the stock in a report on Tuesday, August 8th. Oppenheimer Holdings, Inc. set a $26.00 price target on shares of Vanda Pharmaceuticals and gave the company a “buy” rating in a report on Sunday, October 29th. BidaskClub lowered shares of Vanda Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Friday, August 11th. HC Wainwright set a $18.00 price target on shares of Vanda Pharmaceuticals and gave the company a “buy” rating in a report on Thursday, August 3rd. Finally, Piper Jaffray Companies set a $23.00 price target on shares of Vanda Pharmaceuticals and gave the company a “buy” rating in a report on Thursday, August 3rd. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating and six have given a buy rating to the company’s stock. Vanda Pharmaceuticals has an average rating of “Buy” and an average target price of $22.00.

Vanda Pharmaceuticals Company Profile

Vanda Pharmaceuticals Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapies to address unmet medical needs. Its product portfolio includes HETLIOZ (tasimelteon), Fanapt (iloperidone), Tradipitant (VLY-686), Trichostatin A and AQW051. It offers HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24).

Earnings History for Vanda Pharmaceuticals (NASDAQ:VNDA)

Receive News & Stock Ratings for Vanda Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vanda Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.